Telix Pharmaceuticals Limited Sales And Marketing Expense
Telix Pharmaceuticals Limited (TLPPF) reported Sales And Marketing Expense of $96.77 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-20.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:SalesAndMarketingExpense · last filed 2026-02-20
AUD
| Period end | Sales And Marketing Expense 12 month |
|---|---|
| 2024-12-31 | 85.47M AUD 20-F · filed 2025-02-24 |
| 2023-12-31 | 50.11M AUD 20-F · filed 2025-02-24 |
| 2022-12-31 | 36.31M AUD 20-F · filed 2025-02-24 |
USD
| Period end | Sales And Marketing Expense 12 month |
|---|---|
| 2025-12-31 | $96.77M 20-F · filed 2026-02-20 |
| 2024-12-31 | $55.95M 20-F · filed 2026-02-20 |
| 2023-12-31 | $33.46M 20-F · filed 2026-02-20 |